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Boromycin is a boron-containing polyether macrolide antibiotic isolated from
Streptomyces antibioticus. It was shown to be active against Gram positive bacteria
and to act as an ionophore for potassium ions. The antibiotic is ineffective against Gram
negative bacteria where the outer membrane appears to block access of the molecule
to the cytoplasmic membrane. Here we asked whether boromycin is active against
Mycobacterium tuberculosis which, similar to Gram negative bacteria, possesses an
outer membrane. The results show that boromycin is a potent inhibitor of mycobacterial
growth (MIC50 = 80 nM) with strong bactericidal activity against growing and non-
growing drug tolerant persister bacilli. Exposure to boromycin resulted in a rapid loss of
membrane potential, reduction of the intracellular ATP level and leakage of cytoplasmic
protein. Consistent with boromycin acting as a potassium ionophore, addition of
KCl to the medium blocked its antimycobacterial activity. In contrast to the potent
antimycobacterial activities of the polyether macrolide, its cytotoxicity and haemolytic
activity were low (CC50 = 30 μM, HC50 = 40 μM) with a selectivity index of more
than 300. Spontaneous resistant mutants could not be isolated suggesting a mutation
frequency of less than 10−9/CFU. Taken together, the results suggests that targeting
mycobacterial transmembrane ion gradients may be an attractive chemotherapeutic
intervention level to kill otherwise drug tolerant persister bacilli, and to slow down the
development of genetic antibiotic resistance.
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INTRODUCTION
Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB), remains the biggest
bacterial killer with 1.3 million deaths per year (Zumla et al., 2014). Emergence of genetic
drug resistance and persistence of infection despite extensive chemotherapy represent two
major issues in current TB treatment regimens (Barry et al., 2009; Gengenbacher and
Kaufmann, 2012). TB drugs, like most antibiotics, target speciﬁc macromolecules. Antibiotic
resistance arises mainly from mutations in target genes (Cohen et al., 2014). Genetic
resistance occurs readily in patients due to non-compliance to lengthy (6–24 months)
multi-drug regimens and spatio-temporal pockets of monotherapy (Prideaux et al., 2015).
Persistence of infection is thought to be due to various types of metabolically quiescent
non-growing drug tolerant bacteria. Several culture models have been developed to study
Abbreviations: BCG, Bacille Calmette–Guérin; BORO, boromycin; INH, Isoniazid; TB, tuberculosis.
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persister bacilli in vitro. A ﬁrst type of mycobacterial persister
may pre-exist in growing cultures or is induced upon treatment
of growing cultures with drugs. Isoniazid for instance shows
a bi-phasic kill pattern (Ahmad et al., 2009; de Steenwinkel
et al., 2010). An initial rapid kill is followed by a phase of
reduced killing leaving intact a small subpopulation of drug
tolerant persisters (Keren et al., 2011). A second type of persisters
can be grown in vitro by exposing a replicating culture to
adverse culture conditions. Growth is terminated and the non-
replicating organisms display drug tolerance (Dartois et al., 2009;
Sarathy et al., 2013). The Wayne model of persistence (Wayne
and Hayes, 1996) for instance exposes the obligate aerobe to
hypoxia, a micro-environmental condition demonstrated for TB
lesions in vivo (Lenaerts et al., 2015). Upon oxygen depletion the
whole growing culture shifts down to a state of non-replicating
persistence. A current working model suggests that killing both
persister types may be required to achieve treatment shortening
(Dick, 2001; Barry et al., 2009). Ideally new TB drugs should kill
persister bacilli and show a low propensity for the development
of genetic drug resistance.
Bacterial membrane integrity and its associated homeostatic
functions, such as maintenance of ion gradients, is essential
regardless of the metabolic status of the cell (Hurdle et al.,
2011). The large number of antimicrobial peptides made by the
host validates the membrane as an antibacterial target site and
successful clinical use of a few membrane-targeting antibiotics,
supports this notion (Hurdle et al., 2011). Furthermore,
resistance development to membrane-targeting antibiotics is
expected to be slow as the target is the product of complex
biosynthetic pathways, as opposed to a single macromolecule.
This notion is supported by the slow emergence of resistance
against membrane targeting antibiotics used in the clinic (Hurdle
et al., 2011). Current TB drugs do not target the membrane.
Here, we used boromycin, an old polyether macrolide antibiotic
isolated from Streptomyces antibioticus to ask whether targeting
the mycobacterial membrane may be a chemotherapeutic
intervention level that would achieve both killing of non-growing
persister bacilli and slowing down the development of genetic
drug resistance. Boromycin was the ﬁrst natural product and the
ﬁrst antibiotic found to contain the trace element boron (Hutter
et al., 1967). Its structure was elucidated by degradation studies
and X-ray analysis (Dunitz et al., 1971) and is shown in Figure 1.
Boromycin’s in vitro bactericidal activity was ﬁrst reported in
1967 against Gram positive bacteria. The antibiotic was shown
to act as ionophore causing cellular potassium ion loss leading to
growth arrest and cell death. The compound is ineﬀective against
Gram negative bacteria where the outer membrane appears to
block access of the compound to the cytoplasmic membrane
(Hutter et al., 1967; Pache and Zahner, 1969).
MATERIALS AND METHODS
Strains, Culture Conditions, and
Chemicals
Mycobacterium tuberculosis H37Rv (ATCC 27294) and
M. bovis BCG (ATCC 35734) liquid cultures were grown
FIGURE 1 | Structure of boromycin (Hutter et al., 1967).
in Middlebrook 7H9 broth (BD Difco) supplemented with
0.5% albumin, 0.2% glucose, 0.085% sodium chloride, 0.5%
glycerol, 0.05% Tween 80. Solid medium cultures were grown
on Middlebrook 7H10 agar (BD Difco) supplemented with 0.5%
albumin, 0.2% glucose, 0.085% sodium chloride, 0.5% glycerol,
0.0003% catalase, and 0.006% oleic acid as described previously
(Lakshminarayana et al., 2015). Staphylococcus aureus (ATCC
29213), S. epidermidis (ATCC 14990), Enterococcus faecalis
(ATCC 29212), Escherichia coli (ATCC 25922), Acinetobacter
baumannii (ATCC19606), and Klebsiella pneumonia (ATCC
BAA-1705) liquid cultures were grown in LB media (BD
Difco). To generate hypoxic non-growing mycobacterial
cultures, bacteria were grown in sealed glass tubes with
stirring as described previously (Lim et al., 1999). HepG2
(ATCC HB.8065) and Vero (ATCC CCL-81) cells were cultured
at 37◦C with 5% CO2 atmosphere in DMEM media (Gibco)
complemented with 10% FBS heat-inactivated (Gibco), penicillin
(100 U/mL, Gibco) and streptomycin (100 μg/mL, Gibco).
Red blood cells were obtained from Interstate Blood Bank, Inc.
Laboratory, USA. Boromycin was purchased from AdipoGen.
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), Triton X-100, and isoniazid were purchased from
Sigma–Aldrich.
Growth Inhibition and Bactericidal
Assays
Mininum Inhibitory Concentrations (MICs) were determined
in broth as described previously by the broth dilution
method (Murugasu-Oei and Dick, 2000; Gopal and Dick,
2015; Lakshminarayana et al., 2015) using turbidity (optical
density) as a proxy for growth (Murugasu-Oei and Dick,
2000). We report MIC50 and MIC90, the concentrations that
inhibit 50 and 90% of growth, respectively, as compared to
the untreated control. Bactericidal activities, i.e., ‘Minimal
bactericidal concentration’ (MBC99) for growing bacteria,
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and ‘Wayne cidal concentration’ (WCC99) for hypoxic non-
growing bacilli were determined as described previously
(Murugasu-Oei and Dick, 2000; Lakshminarayana et al., 2015).
Controls of Wayne’s model of hypoxia included treatment
with 5 μM of isoniazid or moxiﬂoxacin resulting in no
any bactericidal activity and 10 fold killing, respectively.
Exponentially growing cultures or hypoxic non-growing
cultures were exposed to various drug concentrations for
5 days and then plated for CFU (colony forming unit)
determination.
Spontaneous Resistant Mutant Selection
Mycobacterium bovis BCG was grown to mid log phase (O.D.
600 = 0.4–0.6) and108 CFU were plated per 7H10 standard agar
plate containing one, two or four times the MIC90 concentration
of boromycin. In order to reach 109 CFU and not overload the
plates, we plated 10 times 108 CFU on 10 diﬀerent plates. The
plates were incubated for a total of 8 weeks (Gopal and Dick,
2015).
Time-Kill, Cell-Content Release,
Membrane Potential, and ATP Level
Determinations
Time-kill curves were determined as follows: 107 CFU inoculum
of M. bovis BCG were treated with MIC90 of boromycin
or Isoniazid and samples were taken at various time points
for CFU determination on agar plates. To assess the eﬀect
of boromycin on the release of cell content, we transformed
M. bovis BCG with plasmid pGMEH-P38-mRFP (Kim et al.,
2011) (pGMEH-P38-mRFP was a gift from Dirk Schnappinger,
Addgene plasmid # 27058) encoding mCherry Red Fluorescent
Protein (mRFP) under the control of a strong promoter. We
subjected this strain for 2 days to MIC90 of INH, boromycin
or left it untreated. Supernatant was collected by two serial
centrifugations. Fluorescence was measured using Tecan Inﬁnite
M200Pro plate reader (λ587/630 nm). Similarly, the eﬀect of
boromycin on the membrane potential was measured using the
Baclight Bacterial Membrane Potential Kit (Life Technologies)
according to the supplier’s recommendations. ATP level was
determined using the BactiterGlo kit (Promega) according to
manufacturer’s recommendations.
Cytotoxicity Assays
The MTS (Promega) reduction assay was used to assess HepG2
(ATCC HB-8065) or Vero (ATCC CCL-8) cell viability after
exposure to boromycin according to manufacturer’s guidelines.
Absorbance was read with a Tecan M200Pro plate reader at
570 nm. Optical density (O.D.) was plotted as a function of drug
concentration and cytocidal concentrations were determined.
CCCP was used as a cytotoxic positive control. Hemolytic
activity of boromycin was evaluated by exposing 106 red blood
cells to two fold serial dilutions of compounds in phosphate-
buﬀered saline for 24 h. Red blood cells were subsequently
centrifuged at 1000 g for 10 min and the supernatant was
collected and homogenized by vortexing. Absorbance was read
at 540 nm. Triton X-100 treated control was used to deﬁne 100%
of hemoglobin release.
RESULTS
Boromycin Kills Growing and
Non-growing Persister Mycobacteria,
Shows a High Selectivity Index, and No
Detectable Resistance
We ﬁrst determined whether boromycin shows anti-
mycobacterial activity or whether the outer membrane of
mycobacteria would, similar to the outer membrane in Gram
negative bacteria, cause intrinsic resistance to the antibiotic.
Virulent M. tuberculosis H37Rv and its closely related, BSL2
compatible, cousin M. bovis BCG were used as testing strains.
The broth dilution method was employed to determine MIC50
and MIC90 (minimum inhibitory concentrations that inhibit
50 and 90% of growth) by turbidity measurements and MBC99
(minimum bactericidal concentration that causes a 100 fold kill)
was obtained by recovering CFU on agar (Murugasu-Oei and
Dick, 2000). We also determined WCC99 (minimum bactericidal
concentration that causes a 100-fold kill in the Wayne model),
i.e., the concentration that kills hypoxic non-replicating persister
bacilli (Lakshminarayana et al., 2015). Table 1 shows that
TABLE 1 | Antibacterial and cytotoxic activities of Boromycin.
Antibacterial activity (µM)
MIC50 MIC90 MBC99 WCC99
M. tuberculosis H37Rv 0.08 0.2 0.2 nd
M. bovis BCG 0.05 0.2 0.2 0.2
S. aureus 0.1 0.3 0.6 na
S. epidermidis 0.1 0.3 0.3 na
E. faecalis 0.15 0.2 0.4 na
E. coli >100 >100 na na
A. baumannii >100 >100 na na







Human red blood cells 40 >50
MIC50/MIC90, minimum inhibitory concentrations that inhibit 50 and 90% growth
of replicating culture, respectively. MBC99, minimum bactericidal concentration that
kills 99% of replicating culture. WCC99, Wayne bactericidal concentration that kills
99% of hypoxic non-replicating culture. CC50/CC90, cytocidal concentration that
kills 50 and 90% of HepG2 and Vero cells, respectively. HC50/HC90, haemolytic
concentration that induces lysis of 50 and 90% of red blood cells, respectively.
n.d., not determined; n.a., not applicable.
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boromycin displayed an attractive growth inhibition potency
with MIC50 values of around 80 nM and bactericidal activity
against both replicating and non-replicating tubercle bacilli
with identical MIC90, MBC99, and WCC99 values of 200 nM.
These results show that boromycin possesses very potent anti-
mycobacterial activity despite the presence of an outer membrane
in this group of bacteria and that its cidal activity is independent
of the replication status of the bacilli, which means that the
antibiotic kills not only aerated growing cultures but also hypoxic
non-growing cultures (Supplementary Figure S1). Table 1 also
shows that boromycin displayed potent growth inhibition and
bactericidal activity against Gram positive pathogens including
S. aureus, S. epidermidis, and E. faecalis but was inactive against
Gram negative bacteria including E. coli, A. baumannii, and
K. pneumoniae conﬁrming previous reports (Hutter et al., 1967).
To determine boromycin’s selectivity index, we measured
cytotoxicity against mammalian HepG2 and Vero cells using
a tetrazolium reduction viability assay (Riss et al., 2004),
and its haemolytic activity against human red blood cells
using an hemoglobin-release assay (Dausset and Contu,
1967). Boromycin’s cytocidal (CC50) and haemolytic (HC50)
concentrations (concentrations that kills 50% of HepG2 or
Vero cells and induces the lysis of 50% of red blood cells), were
shown to be 35, 25, and 40 μM, respectively, (Table 1). These
results suggest that boromycin has a high selectivity for the
mycobacterial membrane with a selectivity index (CC50/MIC50)
of more than 300.
To determine whether boromycin kills growing cultures
completely or whether the antibiotic shows a – for many TB
drugs typical – biphasic kill curve, time-kill experiments were
conducted in which we quantiﬁed the reduction of CFU as a
function of exposure time. Figure 2 shows the typical biphasic
kill curve of isoniazid. After an initial reduction of CFU the curve
levels oﬀ and leaves intact a population of viable non-growing
persister bacteria. In contrast boromycin showed a monophasic
kill curve resulting in an apparent sterilization of the culture.
To determine spontaneous resistance mutation frequencies
for boromycin we plated twice 109 CFU logarithmic phase
M. bovis BCG cultures on agar plates containing one, two or
four times the MIC90 of the antibiotic. No boromycin resistant
colonies could be identiﬁed even after extended incubation
of the selection plates for 8 weeks. This result shows that
the spontaneous resistance mutation frequency of the tubercle
bacillus against boromycin is smaller than 10−9/CFU. In contrast
Isoniazid selection delivered resistant strains at a frequency of
10−6/CFU.
Boromycin Acts as Potassium Ionophore
and Causes Collapse of the Membrane
Potential
Boromycin was previously shown in B. subtilis to act as a
potassium ionophore and to cause loss of the bacterium’s
potassium ion gradient. Addition of potassium salt to the
medium – but not addition of (divalent) magnesium salt blocked
the growth inhibitor activity of the drug (Pache and Zahner,
1969). We tested the protective eﬀect of high concentrations of
FIGURE 2 | Time-kill curve of boromycin compared to Isoniazid.
Exponentially growing cultures of Mycobacterium bovis BCG were treated
with boromycin (BORO, 0.2 μM = 1x MIC90) or Isoniazid (INH, 0.5 μM = 1x
MIC90) and CFU were enumerated at the time points indicated. Experiments
were conducted three times. Shown are the averages with standard
deviations. LOD, limit of detection (30 CFU/ml).
potassium (20 mg/mL) or magnesium (10 mg/mL) cations in
the culture media while subjecting M. bovis BCG to boromycin
treatment at MIC50. In standard broth, we observed the expected
50% growth inhibition eﬀect (Figure 3A). This growth inhibition
was reduced to 10% in presence of KCl whereas it was unaﬀected
by the addition of MgCl2 (Figure 3A). In contrast, addition of
KCl did not aﬀect growth inhibition by isoniazid (Supplementary
Figure S2). These results suggest that boromycin’s mechanism of
action against mycobacteria is similar to its actions against Gram
positive bacteria, which is to say that the polyether macrolide
appears to act as a potassium ionophore. We also tested whether
the medium pH inﬂuenced the growth inhibitory activity of
the antibiotic (pH 5.5, 6.4, and 9), which was not the case
(Supplementary Figure S3), consistent with boromycin’s neutral
(i.e., not involving protons) carrier property (Hutter et al.,
1967).
If boromycin indeed acts as an ionophore and causes the
collapse of the potassium gradient across the bacillus’ membrane
we expect to see an eﬀect of the compound on the membrane
potential. To determine whether this is the case, we measured
the eﬀect of the antibiotic on the membrane potential employing
the 3,3-Diethyloxacarbocyanine iodide (DiOC2) probe which
accumulates in cells in a membrane potential-dependent manner
(Novo et al., 2000). Upon accumulation, the dye forms aggregates
that emit a red ﬂuorescence signal (λ488/630 nm) whereas a
reduced membrane potential prevents accumulation and results
in green ﬂuorescence emission (λ488/520 nm), that is the
red/green ratio reﬂects the membrane potential status. Figure 3B
shows that as expected, boromycin treatment caused a marked
depolarization of the membrane as illustrated by the drop
in the red/green ratio, similar to the eﬀect of the uncoupler
carbonyl cyanide m-chloro phenyl hydrazone (CCCP). In
comparison, isoniazid treatment aﬀected the membrane potential
only moderately. To characterize the cellular consequences of
boromycin exposure and collapse of the membrane potential
further, we measured the impact of the ionophore on the
cellular ATP level. ATP synthesis requires membrane polarization
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FIGURE 3 | Mechanism of action of boromycin. (A) Effect of cations added to the medium on growth inhibition by boromycin. Exponentially growing M. bovis
BCG culture was exposed to MIC50 (0.05 μM) boromycin either in standard medium (Mock) or to medium with added potassium chloride (+KCl, 20 mg/ml) or
magnesium chloride (+MgCl2, 10 mg/ml). The effect on growth was determined by turbidity measurement after 5 days. Percent inhibition compared to
boromycin-free control cultures grown in standard medium is shown. (B) Effect of boromycin on the membrane potential. Exponentially growing M. bovis BCG
culture was exposed to MIC90 (0.2 μM) boromycin for 2 days after which the membrane potential was measured by the DiOC2, (3,3′-Diethyloxacarbocyanine Iodide)
fluorescence assay (see Materials and Methods). Carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 50 μM), positive control. INH, Isoniazid MIC90 (0.5 μM).
(C) Effect of boromycin on the intracellular ATP level. Exponentially growing M. bovis BCG culture was exposed to MIC90 (0.2 μM) boromycin for 2 days after which
the ATP content was measured was measured by ATP-dependent luciferin/luciferase assay (see Materials and Methods). INH, Isoniazid MIC90 (0.5 μM). RLU,
relative luminescence unit. (D) Effect of boromycin on cytoplasmic protein leakage. Exponentially growing M. bovis BCG culture was exposed to MIC90 (0.2 μM)
boromycin for 2 days after which release of Red fluorescence protein (RFP) was measured in the supernatant. INH, Isoniazid, MIC90 (0.5 μM). RFU, relative
fluorescence unit. B.B: positive control, culture disrupted by bead beating. (A–D): Shown are the averages of three independent experiments with standard
deviations and Student T-test statistical significances given by a two-tailed P values with ∗p < 0.05 and ∗∗p < 0.01.
and we predicted that boromycin treatment would results in
a marked reduction in ATP level. We used the BactiterGlo
kit which makes use of the ATP-dependent luciferin/luciferase
reaction to measure ATP. Figure 3C shows a drastic reduction
of the ATP level upon boromycin exposure, which was not
observed upon Isoniazid treatment as reported by others
(Koul et al., 2014). Finally, we show in Figure 3D that
boromycin treatment results in leakage of cytoplasmic protein.
We employed a strain expressing a plasmid-encoded red
ﬂuorescent protein (λ587/630 nm) and subjected cultures to
MIC90 of boromycin. We used centrifugation to pellet the treated
cultures and measured the cell-content release, reﬂected by the
red ﬂuorescence signal measured in the supernatant. Cultures
disrupted by bead beating were used as a positive control.
Boromycin treatment correlated with a marked cell-content
release as reﬂected by the increase in red ﬂuorescence. Treatment
with Isoniazid was associated with a moderate increase in
the ﬂuorescence signal. It has previously been suggested that
isoniazid treatment leads to moderate cell lysis (Vilcheze et al.,
2000).
DISCUSSION
Boromycin is a polyether macrolide antibiotic with selective
activity against Gram positive bacteria where it acts as ionophore
for potassium ions. The antibiotic is ineﬀective against Gram
negative bacteria where the outer membrane appears to block
access of the compound to the cytoplasmic membrane. Here
we show boromycin is active againstMycobacterium tuberculosis
which, similar to Gram negative bacteria, possesses an outer
membrane. Boromycin is a potent, submicromolar inhibitor of
mycobacterial growth with submicromolar bactericidal activity
against growing and non-growing drug tolerant persister bacilli.
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Exposure to boromycin resulted in a loss of membrane
potential, reduction of the intracellular ATP level and leakage
of cytoplasmic protein. Consistent with boromycin acting
as a potassium ionophore addition of KCl to the medium
blocked its antimycobacterial activity. In contrast to the potent
antimycobacterial activities cytotoxicity and haemolytic activity
were low with a selectivity index of more than 300. Spontaneous
resistant mutants could not be isolated indicating a very
low spontaneous resistance mutation frequency of less than
10−9/CFU.
Ionophores are currently not being used in medicine
mainly because of their generally poor selectivity. However,
these antibiotics are widely in use in livestock veterinarian
medicine (Russell and Strobel, 1989). It is interesting to
note that this class of molecules recently gained attention as
potential anti-cancer agents. Salinomycin, another polyether
monovalent cation ionophore, has been shown to possess
high speciﬁcity against cancer stem cells (Gupta et al.,
2009) and has now entered clinical trial studies (Zhou
et al., 2013). Similar compounds are actively considered for
their antibacterial and anti-parasitic properties (Huczynski,
2012; Huczynski et al., 2012; Antoszczak et al., 2014a,b,c;
D’Alessandro et al., 2015). Here we add to the growing
list of potentially therapeutically interesting ionophores: we
identiﬁed boromycin as a potent and selective antimycobacterial
compound. Further studies will determine the eﬃcacy of this
new antimycobacterial in TB mouse models. Our ﬁndings
also suggest that it may be worthwhile to consider a so
far underexplored approach in TB drug discovery: targeting
the mycobacterial cell membrane as opposed to speciﬁc
macromolecules may represent an attractive strategy to
slow down genetic resistance development. Importantly,
this chemotherapeutic intervention level appears to be an
eﬀective way to kill drug tolerant persister bacilli. Therefore,
membrane function targeting agents could contribute to the
development of novel treatment shortening anti-TB combination
regimens.
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